Durata Therapeutics Company Profile (NASDAQ:DRTX)

About Durata Therapeutics (NASDAQ:DRTX)

Durata Therapeutics logoDurata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:DRTX
  • CUSIP: 26658A10
  • Web: N/A
Average Prices:
  • 200 Day Moving Avg: $19.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.64
  • P/E Growth: 0
  • Dividend Yield: 1.0%

Frequently Asked Questions for Durata Therapeutics (NASDAQ:DRTX)

What is Durata Therapeutics' stock symbol?

Durata Therapeutics trades on the NASDAQ under the ticker symbol "DRTX."

Who are some of Durata Therapeutics' key competitors?

How do I buy Durata Therapeutics stock?

Shares of Durata Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Durata Therapeutics' stock price today?

One share of Durata Therapeutics stock can currently be purchased for approximately $24.16.

MarketBeat Community Rating for Durata Therapeutics (NASDAQ DRTX)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  157
MarketBeat's community ratings are surveys of what our community members think about Durata Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Durata Therapeutics (NASDAQ:DRTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Durata Therapeutics (NASDAQ:DRTX)
Price Target History for Durata Therapeutics (NASDAQ:DRTX)
Analysts' Ratings History for Durata Therapeutics (NASDAQ:DRTX)
No equities research coverage for this company has been tracked by MarketBeat.com


Earnings History for Durata Therapeutics (NASDAQ:DRTX)
Earnings by Quarter for Durata Therapeutics (NASDAQ:DRTX)
Earnings History by Quarter for Durata Therapeutics (NASDAQ DRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2014Q2($0.73)($0.61)ViewN/AView Earnings Details
5/8/2014Q114($0.61)($0.65)ViewN/AView Earnings Details
3/14/2014Q413($0.76)($0.59)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.52)($0.75)ViewN/AView Earnings Details
5/9/20131Q13($0.66)($0.86)ViewN/AView Earnings Details
11/9/2012Q312($1.00)($1.47)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Durata Therapeutics (NASDAQ:DRTX)
Current Year EPS Consensus Estimate: $-2.97 EPS
Next Year EPS Consensus Estimate: $-1.37 EPS


Dividend History for Durata Therapeutics (NASDAQ:DRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Durata Therapeutics (NASDAQ:DRTX)
Insider Trades by Quarter for Durata Therapeutics (NASDAQ:DRTX)
Insider Trades by Quarter for Durata Therapeutics (NASDAQ:DRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/12/2014John Patrick Shannon JrInsiderBuy3,000$13.72$41,160.00View SEC Filing  
6/12/2014Paul R EdickCEOBuy3,000$15.23$45,690.00View SEC Filing  
5/12/2014Schutter Richard DeDirectorBuy15,000$15.57$233,550.00View SEC Filing  
3/21/2014Aisling Capital Iii Lpmajor shareholderSell100,649$15.74$1,584,215.26View SEC Filing  
12/3/2013Lisa GilesDirectorBuy1,000$10.95$10,950.00View SEC Filing  
5/20/2013Paul R EdickCEOBuy3,000$7.09$21,270.00View SEC Filing  
8/14/2012Paul R EdickCEOBuy5,000$8.65$43,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Durata Therapeutics (NASDAQ:DRTX)
Latest Headlines for Durata Therapeutics (NASDAQ:DRTX)
No headlines for this company have been tracked by MarketBeat.com



Durata Therapeutics (DRTX) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.